PepGen Inc.

NASDAQ: PEPG · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0001835597Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 53DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$89.7M

Employees

as of 2026-08-14

Market cap

$206.1M

as of 2026-08-14

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$89.7M-$89.7M2025

Operating income-$93.6M-$93.6M2025

Total assets$173.9M$173.9M2025

Liabilities$26.5M$26.5M2025

Equity$147.4M$147.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is PepGen Inc.’s financial profile?

PepGen Inc. earned -$89.7M in FY2025 net income.

Peers · Healthcare

Immunic, Inc.——AN2 Therapeutics, Inc.——Galectin Therapeutics Inc.——Cardiol Therapeutics Inc.——Atrium Therapeutics, Inc.——Acumen Pharmaceuticals, Inc.——

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M76B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B66B PTC Inc.$2.7B83B+

Key facts

CEOJames McArthur

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: PEPG

Employees59

IPO date2022-05-06

Latest filings

8-K2026-08-06 10-Q2026-08-06 8-K2026-06-22 8-K2026-05-21 10-Q2026-05-12 8-K2026-05-12 DEF 14A2026-04-28 8-K2026-03-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.